| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
JAK/STAT signaling pathway (stimulates); interferon-α stimulated genes (induces expression).
|
|---|---|
| ln Vitro |
In vitro, Dimethyl biphenyl-4,4'-dicarboxylate stimulates JAK/STAT signaling and induces the expression of interferon-α stimulated genes in a HepG2 cell line at 250 µg/ml. Quantitative IC50 values are not detailed in publicly available sources.
|
| ln Vivo |
In vivo, Dimethyl biphenyl-4,4'-dicarboxylate is used as a hepatoprotectant in the treatment of chronic hepatitis. Detailed dose-response and pharmacokinetic data are limited in publicly available literature.
|
| Enzyme Assay |
No specific cell-free enzyme/receptor binding assay protocol is detailed for this compound. For hepatoprotective compounds, typical cell-free assays include enzyme inhibition studies or receptor binding assays.
|
| Cell Assay |
Cellular activity is assessed in HepG2 hepatoma cells. Cells are treated with Dimethyl biphenyl-4,4'-dicarboxylate at 250 µg/ml, and endpoints include JAK/STAT signaling activation (Western blot for phosphorylated STAT proteins) and interferon-α stimulated gene expression (qPCR).
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of chronic hepatitis or liver injury. Dimethyl biphenyl-4,4'-dicarboxylate is administered orally. Endpoints include serum liver enzyme levels (ALT, AST), histopathological examination of liver tissue, and survival.
|
| ADME/Pharmacokinetics |
Molecular weight: 270.28 g/mol; molecular formula: C16H14O4. CAS No.: 792-74-5. Purity: typically ≥98%. Appearance: solid. Solubility: soluble in organic solvents. Storage: typical for organic compounds (desiccated, protected from light).
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a hepatoprotectant used in chronic hepatitis, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development.
|
| Additional Infomation |
Nisel has been studied for its potential use in treating chronic liver disease.
Dimethyl biphenyl-4,4'-dicarboxylate is a research-grade compound and has been used as a hepatoprotectant in the treatment of chronic hepatitis. It is not FDA-approved in the US but may be used in some regions. Its mechanism involves JAK/STAT signaling stimulation and induction of interferon-α stimulated genes. |
| Molecular Formula |
C16H14O4
|
|---|---|
| Molecular Weight |
270.27996
|
| Exact Mass |
270.089
|
| CAS # |
792-74-5
|
| Related CAS # |
Dimethyl biphenyl-4,4'-dicarboxylate-d8;1219803-50-5
|
| PubChem CID |
13099
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
407.0±38.0 °C at 760 mmHg
|
| Melting Point |
213-215 °C(lit.)
|
| Flash Point |
204.7±25.2 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.559
|
| LogP |
3.71
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
20
|
| Complexity |
302
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C=CC(C2C=CC(C(OC)=O)=CC=2)=CC=1)OC
|
| InChi Key |
BKRIRZXWWALTPU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14O4/c1-19-15(17)13-7-3-11(4-8-13)12-5-9-14(10-6-12)16(18)20-2/h3-10H,1-2H3
|
| Chemical Name |
methyl 4-(4-methoxycarbonylphenyl)benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2 mg/mL (~7.40 mM)
DMF : 2 mg/mL (~7.40 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6999 mL | 18.4993 mL | 36.9987 mL | |
| 5 mM | 0.7400 mL | 3.6999 mL | 7.3997 mL | |
| 10 mM | 0.3700 mL | 1.8499 mL | 3.6999 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
